Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Investor Newsletters
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

General Meeting

13 May 2025

Videocast of the Annual General Meeting held on May 13, 2025 in Paris, France

13 May 2025

GenSight Biologics Announces Approval of All Resolutions Supported by the Board of Directors at the Combined General Meeting of May 13, 2025

23 April 2025

GenSight Biologics Annual General Meeting on May 13, 2025

30 May 2024

Gensight Biologics announces the approval of all resolutions supported by the Board of Directors at its Combined General Meeting

07 May 2024

Annual General Meeting on May 29, 2024

21 Mar 2023

Annual General Meeting on June 21, 2023

10 May 2023

GenSight Biologics Announces the Filing of its 2022 Universal Registration Document and Reschedules its Annual General Meeting on June 21, 2023

04 May 2022

Annual General Meeting on May 25, 2022 Procedures for obtaining preparatory documents for the General Meeting

29 Apr 2021

Annual General Meeting 2021

08 April 2021

Annual General Meeting on April 29, 2021

  • 1
  • 2
  • View next 9 articles
© 2025 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page